Research programme: antibody drug conjugates - Avicenna Oncology

Drug Profile

Research programme: antibody drug conjugates - Avicenna Oncology

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator Avicenna Oncology
  • Class Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 04 Aug 2016 Research programme: antibody drug conjugates - Avicenna Oncology is available for licensing as of 21 Jul 2016. http://www.avicenna-oncology.com/
  • 15 Jul 2016 Early research in Cancer in Switzerland (unspecified route) (Avicenna Oncology pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top